All In Biotech

Drug Trial Radar · NCT04750226

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

118

Actual

Start

Feb 18, 2021

Primary completion

Apr 27, 2026

Study completion Apr 27, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effective ABBV-951 is in adult participants with PD. Adverse events and change in disease activity is evaluated. ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given as an infusion under the skin for the treatment of Parkinson's Disease. Adult participants with advanced PD and who have completed M15-736 or M20-339 study will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 60 sites in the United States and Australia. Participants will receive continuous subcutaneous infusion (CSCI) (under the skin) of ABBV-951 for 96 weeks during the Primary Treatment Period and during the optional Extended Treatment Period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical and remote telephone assessments, blood tests, checking for side effects, and completing questionnaires.

Conditions

  • Parkinson's Disease (PD)

Interventions

  • ABBV-951Drug

    Solution for continuous subcutaneous infusion (CSCI).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Adverse Event (AEs)Time frame: Up to Week 96
  2. Percentage of Participants with AEs of Special Interest (AESIs)Time frame: Up to Week 96
  3. Percentage Of Participants With Numeric Grade Equal To Or Higher Than 5 On The Infusion Site Evaluation ScaleTime frame: Up To Week 96
  4. Percentage Of Participants With Letter Grade Equal To Or Higher Than D On The Infusion Site Evaluation ScaleTime frame: Up To Week 96
  5. Change From Baseline in Suicidality as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up To Week 96
  6. Change From Baseline in Impulsive-Compulsive Disorders and related behaviors as assessed in Parkinson's Disease- Rating Scale (QUIP-RS)Time frame: Up To Week 96
  7. Change From Baseline in Cognitive Impairment as Assessed by the Mini-Mental State Examination (MMSE)Time frame: Up To Week 96
  8. Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed.Time frame: Up to Week 96
  9. Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements like Systolic and Diastolic Blood Pressure will be AssessedTime frame: Up to Week 96
  10. Change From Baseline in Electrocardiograms (ECGs)Time frame: Up to Week 96

Locations

52 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - Main /ID# 217814

    Birmingham, Alabama

  • Usa Mitchell Cancer Institute /ID# 218467

    Mobile, Alabama

  • Xenoscience, Inc /ID# 222515

    Phoenix, Arizona

  • Muhammad Ali Parkinson Center /ID# 218609

    Phoenix, Arizona

  • Movement Disorders Center of Arizona /ID# 218471

    Scottsdale, Arizona

  • Neuro Pain Research Center /ID# 217720

    Fresno, California

  • Loma Linda University Medical /ID# 217724

    Loma Linda, California

  • University of California, Los Angeles /ID# 218460

    Los Angeles, California

  • SC3 Research Group - Pasadena /ID# 223018

    Pasadena, California

  • University of California, San /ID# 218595

    San Diego, California

  • Duplicate_Cedars-Sinai Medical Center-West Hollywood /ID# 218607

    West Hollywood, California

  • University of Colorado Hospital /ID# 218486

    Aurora, Colorado

  • Alpine Clinical Research Center /ID# 218461

    Boulder, Colorado

  • Denver Neurological Research, LLC /ID# 217811

    Denver, Colorado

  • CenExel Rocky Mountain Clinical Research, LLC /ID# 217731

    Englewood, Colorado

  • Georgetown University Hospital /ID# 218599

    Washington D.C., District of Columbia

  • Visionary Investigators Network - Miami /ID# 217726

    Miami, Florida

  • Renstar Medical Research /ID# 217837

    Ocala, Florida

  • Neurology Associates Ormond Beach /ID# 217800

    Ormond Beach, Florida

  • Parkinson's Disease Treatment Center of Southwest Florida /ID# 222679

    Port Charlotte, Florida

  • University of South Florida- Neuroscience Institute /ID# 218481

    Tampa, Florida

  • Premiere Research Institute - Palm Beach /ID# 218743

    West Palm Beach, Florida

  • Rush University Medical Center /ID# 217807

    Chicago, Illinois

  • University of Chicago Medical Center /ID# 218611

    Chicago, Illinois

  • St Elizabeth's Medical Center - Brighton /ID# 223082

    Brighton, Massachusetts

  • St. Lukes Hosp. of Kansas City /ID# 218604

    Kansas City, Missouri

  • Washington University-School of Medicine /ID# 217723

    St Louis, Missouri

  • Global Neurosciences Institute /ID# 218472

    Lawrenceville, New Jersey

  • Northwell Health /ID# 218600

    Lake Success, New York

  • M3 Wake Research - Raleigh /ID# 218482

    Raleigh, North Carolina

  • The Orthopedic Foundation /ID# 218608

    New Albany, Ohio

  • The Movement Disorder Clinic of Oklahoma /ID# 218580

    Tulsa, Oklahoma

  • Legacy Medical Group - Neurology /ID# 217804

    Portland, Oregon

  • University of Pennsylvania /ID# 218605

    Philadelphia, Pennsylvania

  • Thomas Jefferson University Hospital /ID# 218594

    Philadelphia, Pennsylvania

  • Prisma Health-Upstate /ID# 217803

    Greenville, South Carolina

  • Coastal Neurology /ID# 222893

    Port Royal, South Carolina

  • KCA Neurology - Franklin /ID# 222811

    Franklin, Tennessee

  • Vanderbilt University Medical Center /ID# 217722

    Nashville, Tennessee

  • St. David's Healthcare Partnership, L.P., LLP /ID# 248148

    Austin, Texas

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.